About Pediatric Asthma
Asthma is a chronic disorder characterized by inflammation of the air passages, resulting in the temporary narrowing of the airways that transport air from the nose and mouth to the lungs.(3, 2) Asthma symptoms, such as coughing, wheezing, and shortness of breath, can occur and can impact multiple aspects of patients' lives.(3) Asthma is the most common chronic condition among children, and it is the cause of almost three million physician visits and 200,000 hospitalizations among children each year in the United States.(2, 8) It is also the third leading cause of hospitalization among children.(2)
ASMANEX 110 mcg has not been demonstrated to be effective in treating asthma symptoms caused by specific asthma triggers.
The U.S. Food and Drug Administration (FDA) approved the use of ASMANEX 110 mcg for the maintenance treatment of asthma as a preventive therapy in patients 4 to 11 years of age in February 2008. The approval was based in part on results from a 12-week placebo-controlled trial of 296 patients 4 to 11 years of age who had been diagnosed with mild to moderate persistent asthma for at least six months. Results showed significant improvement in percent predicted FEV1 (forced expiratory volume in one second) from baseline to endpoint in patients treated with ASMANEX 110 mcg once-daily, in the evening, compared to placebo (P=0.002). In this study, secondary endpoints of morning and evening peak expiratory flow and rescue medication use were supportive of the efficacy of ASMANEX. The only approved dose for children 4 to 11 is 110 mcg (1 puff) administered once daily in the evening.
ASMANEX was discovered and developed by Schering-Plough Research
Institute and is currently approved for asthma treatment in more than 40
countries. ASMANEX offers an effective inhaled corticosteroid to help
manage asthma symptoms in a device that was awarded the DuPont Award for
|SOURCE Schering-Plough Corporation|
Copyright©2008 PR Newswire.
All rights reserved